Search Within

Neil Jayendra Shah

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (53)
  2. Journal Article (29)
  3. Conference Paper (1)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (85)
  2. Genitourinary Oncology Service (85)
  3. Solid Tumor Oncology Division (85)
  4. Hematologic Malignancies, Division of (32)
  5. Weinberg Fellows (32)
  6. Population Sciences Research Program (25)

More Groups

People
  1. Robert Motzer (37)
  2. Ritesh Kotecha (27)
  3. Martin Voss (25)
  4. Maria Carlo (22)
  5. Darren Feldman (21)
  6. David Aggen (21)

More People

Years
  1. 2025 (10)
  2. 2024 (19)
  3. 2023 (22)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (44)
  2. Journal for ImmunoTherapy of Cancer (7)
  3. Cancers (4)
  4. The Oncologist (3)
  5. Annals of Oncology (2)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (46)
  2. Biomed Central Ltd (7)
  3. Oxford University Press (6)
  4. MDPI (5)
  5. American Association for Cancer Research (3)
  6. Elsevier BV (3)

More Publishers

Results (85)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era
    Journal Article

    Shah, N. J.; Sura, S. D.; Shinde, R.; Shi, J.; Singhal, P. K.; Robert, N. J.; Vogelzang, N. J.; Perini, R. F.; Motzer, R. J.
    European Urology Open Science (2023)

    Fulltext@MSK | Save
  • Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Gedvilaite, E.; Ptashkin, R.; Knezevic, A.; Murray, S.; Johnson, I.; Shapnik, N.; Feldman, D. R.; Carlo, M. I.; Shah, N. J.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models
    Meeting Abstract

    Zhang, Y.; Gupta, S.; Belouali, A.; Lev-Ari, S.; Shah, N.; Krishnamurthy, K.; Serzan, M.; Alaoui, A.; McGarvey, P.; Atkins, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors
    Meeting Abstract

    McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): A matched cohort study from the International Catch-It Consortium
    Meeting Abstract

    El Zarif, T.; Nassar, A.; Adib, E.; Fitzgerald, B.; Huang, J.; Mouhieddine, T.; Nonato, T.; McKay, R.; Li, M.; Mittra, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N)
    Meeting Abstract

    Shah, N. J.; Shinde, R.; Moore, K.; Sainski-Nguyen, A.; Le, L.; Cao, F.; Song, R.; Singhal, P.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)
    Meeting Abstract

    Shah, N. J.; Beckermann, K.; Vogelzang, N. J.; Mao, S. S.; Ornstein, M. C.; Hammers, H. J.; Gao, X.; McDermott, D. F.; Haas, N. B.; Yan, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer
    Meeting Abstract

    Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Choueiri, T. K.; McGregor, B. A.; Shah, N. J.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Oliver, J. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save